Imperial College London
Portrait Picture

Dr Yen F Tai

Faculty of Medicine, Department of Brain Sciences

Honorary Clinical Senior Lecturer
 
 
 
//

Contact

 

+44 (0)20 3311 1182yen.tai

 
 
//

Location

 

Department of NeurologyCharing Cross HospitalCharing Cross Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Hvingelby:2022:10.1136/bmjno-2022-000333,
author = {Hvingelby, VS and Højholt, Terkelsen M and Johnsen, EL and Møller, M and Danielsen, EH and Henriksen, T and Glud, AN and Tai, Y and Møller, Andersen AS and Meier, K and Borghammer, P and Moro, E and Sørensen, JCH and Pavese, N},
doi = {10.1136/bmjno-2022-000333},
journal = {BMJ Neurology Open},
pages = {e000333--e000333},
title = {Spinal cord stimulation therapy for patients with Parkinson’s disease and gait problems (STEP-PD): study protocol for an exploratory, double-blind, randomised, placebo-controlled feasibility trial},
url = {http://dx.doi.org/10.1136/bmjno-2022-000333},
volume = {4},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Introduction Gait difficulties are common in Parkinson’s disease (PD) and cause significant disability. These symptoms are often resistant to treatment. Spinal cord stimulation (SCS) has been found to improve gait, including freezing of gait, in a small number of patients with PD. The mechanism of action is unclear, and some patients are non-responders. With this double-blind, placebo-controlled efficacy and feasibility clinical and imaging study, we aim to shed light on the mechanism of action of SCS and collect data to inform development of a scientifically sound clinical trial protocol. We also aim to identify clinical and imaging biomarkers at baseline that could be predictive of a favourable or a negative outcome of SCS and improve patient selection.Methods and analysis A total of 14 patients will be assessed with clinical rating scales and gait evaluations at baseline, and at 6 and 12 months after SCS implantation. They will also receive serial 18F-deoxyglucose and 18FEOBV PET scans to assess the effects of SCS on cortical/subcortical activity and brain cholinergic function. The first two patients will be included in an open pilot study while the rest will be randomised to receive active treatment or placebo (no stimulation) for 6 months. From this point, the entire cohort will enter an open label active treatment phase for a subsequent 6 months.Ethics and dissemination This study was reviewed and approved by the Committee on Health Research Ethics, Central Denmark RM. It is funded by the Danish Council for Independent Research. Independent of outcome, the results will be published in peer-reviewed journals and presented at national and international conferences.Trial registration number NCT05110053; ClinicalTrials.gov Identifier.
AU  - Hvingelby,VS
AU  - Højholt,Terkelsen M
AU  - Johnsen,EL
AU  - Møller,M
AU  - Danielsen,EH
AU  - Henriksen,T
AU  - Glud,AN
AU  - Tai,Y
AU  - Møller,Andersen AS
AU  - Meier,K
AU  - Borghammer,P
AU  - Moro,E
AU  - Sørensen,JCH
AU  - Pavese,N
DO  - 10.1136/bmjno-2022-000333
EP  - 000333
PY  - 2022///
SN  - 2632-6140
SP  - 000333
TI  - Spinal cord stimulation therapy for patients with Parkinson’s disease and gait problems (STEP-PD): study protocol for an exploratory, double-blind, randomised, placebo-controlled feasibility trial
T2  - BMJ Neurology Open
UR  - http://dx.doi.org/10.1136/bmjno-2022-000333
UR  - https://neurologyopen.bmj.com/content/4/2/e000333
UR  - http://hdl.handle.net/10044/1/99392
VL  - 4
ER  -
Download